IMC Chicago’s Sage Therapeutics SAGE Stock Holding History

IMC Chicago’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-19,400	Closed	-$1.4M	–	894
2019 Q4	$1.4M	Buy	+19,400	New	+$2.39M	﹤0.01%	580
2019 Q1	–	Sell	-14,000	Closed	-$1.34M	–	855
2018 Q4	$1.34M	Buy	+14,000	New	+$1.6M	﹤0.01%	409

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

IMC Chicago's SAGE Position: Q1 2019 in Review

IMC Chicago sold out of Sage Therapeutics (SAGE) in Q1 2019, closing a stake of 4,212 shares — an estimated $403K sold.

IMC Chicago first reported a position in SAGE in Q4 2018 and held it in 1 quarter. The position peaked at $403K in Q4 2018. 267 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

IMC Chicago reported no remaining Sage Therapeutics position as of Q1 2019 after selling out during the quarter.
IMC Chicago sold 4,212 Sage Therapeutics shares in Q1 2019, an estimated $403K.
IMC Chicago first reported a position in Sage Therapeutics in Q4 2018 and held it in 1 quarter.
IMC Chicago's Sage Therapeutics position peaked at $403K in Q4 2018.
267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on IMC Chicago's 13F filing for Q1 2019, filed 15 May 2019.